Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.

ABSTRACT:

Purpose

Thymic epithelial tumors are rare malignancies, and there is no standard treatment for patients with advanced disease in whom chemotherapy has failed. Antitumor activity of histone deacetylase (HDAC) inhibitors in this disease has been documented, including one patient with thymoma treated with the pan-HDAC inhibitor belinostat.

Patients and methods

Patients with advanced thymic epithelial malignancies in whom at least one line of platinum-containing chemotherapy had failed were eligible for this study. Other eligibility criteria included adequate organ function and good performance status. Belinostat was administered intravenously at 1 g/m(2) on days 1 to 5 of a 21-day cycle until disease progression or development of intolerance. The primary objective was response

SUBMITTER: Giaccone G 

PROVIDER: S-EPMC3107761 | biostudies-literature | 2011 May

REPOSITORIES: biostudies-literature